Coupling an EML4-ALK–centric interactome with RNA interference identifies sensitizers to ALK inhibitors-Reference-Cited by-同舟云学术

Coupling an EML4-ALK–centric interactome with RNA interference identifies sensitizers to ALK inhibitors

Published:2016-10-18 Issue:450 Volume:9 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Zhang Guolin¹,Scarborough Hannah²,Kim Jihye³,Rozhok Andrii I.²,Chen Yian Ann⁴,Zhang Xiaohui⁵,Song Lanxi¹,Bai Yun¹,Fang Bin⁶,Liu Richard Z.⁴,Koomen John⁷,Tan Aik Choon³,Degregori James²,Haura Eric B.¹

Affiliation:

1. Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

2. Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

3. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

4. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

5. Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

6. Proteomics Core Facility, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

7. Department of Molecular Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

Abstract

A network built around the kinase ALK reveals potential targets to enhance ALK inhibitor efficacy in some lung cancer patients.

Funder

National Cancer Institute

Moffitt Cancer Center SPORE in Lung Cancer

Moffitt Lung Cancer Center of Excellence

Colorado Lung Cancer SPORE in Lung Cancer

Research Project Grant

NCI

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference76 articles.

1. A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes

2. Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation

3. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

4. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

5. A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer-associated fibroblasts confer ALK inhibitor resistance inEML4-ALK-driven lung cancer via concurrent integrin and MET signaling;2024-08-28

2. Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK non-small cell lung cancer;2024-03-29

3. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling;Molecular Cancer Therapeutics;2023-09-25

4. EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries;Molecular Oncology;2023-05-15

5. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression;Proceedings of the National Academy of Sciences;2023-02-15